SK&S advised Velocity Clinical Research on the acquisition of ClinMedica Research

SK&S’ transaction team advised Velocity Clinical Research Inc.—the leading multi-specialty clinical sites business, in the acquisition of its first site in Poland—ClinMedica Research in Skierniewice.

Velocity is the leading integrated site organisation for clinical trials. With over 90 sites and more than 220 investigators, Velocity partners with pharmaceutical and biotechnology companies to research new drugs, medical devices, diagnostics, and combination products.

ClinMedica provides clinical research and specialised medical care services, offering innovative therapeutic solutions and the latest treatments. The facility is recognised as one of the best research centers in the country. Conducting clinical trials in many therapeutic areas, it is focused on expanding its research capabilities in ophthalmology and oncology.

This acquisition of ClinMedica marks Velocity’s tenth site in Europe, in addition to its four sites in Germany and five in the United Kingdom. The new acquisition marks the start of Velocity’s expansion in Poland and is the first acquisition among the key ones planned by the company in Poland before the end of the year.

SK&S’ transaction team advised on all stages of the transaction process, including the due diligence as well as the preparation and negotiation of the transaction documentation.

SK&S’ transaction team was led by partner Krzysztof Pawlisz and included Karol Skibniewski (Senior Counsel), Magdalena Rożek (Associate) and Piotr Mordzonek (Associate). The transaction team was supported by Piotr Andrzejak (Partner; tax law), dr. Tomasz Grabka (Senior Associate, tax law), Katarzyna Juralewicz (Associate; tax law), Agnieszka Fedor (Partner; labor law), Jacek Myszko (Partner; life sciences), Ewelina Woike-Reguła (Associate; life sciences) and Natalia Łabęda (Senior Associate; real estate), among others.

During the execution of the transaction, SK&S remained in close cooperation with Dominic Clavell (Executive Vice President, Europe, Velocity Clinical Research) and Agnieszka Gackowska (Vice President and Country Head, Poland, Velocity Clinical Research).

The seller was advised by Loewen Kaczmarek Zawadowski.

More information about the transaction is available HERE.